SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

MELANIA CRYPTO is trending amid discussions surrounding an upcoming movie or documentary release, which some community members anticipate could drive a price surge. Conversely, a significant portion of the community views the token as a 'shitcoin' or 'scam,' frequently referencing past losses and alleged 'pump and dump' activity.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO's fervent community is championing the "OG meme" narrative, positioning Rage Comics as a foundational "meme reset" for the crypto market by actively developing an ecosystem with platforms like RageMaker and RageGames. Enthusiasts express strong conviction, rallying others to "Return to the Memes" and "Rage On" to assert dominance in the sector.

Trump For President

The distribution of a new cryptocurrency to Trump Media shareholders is driving conversations around TRUMP CRYPTO, eliciting both fervent anticipation for the crypto dividend and sharp criticism as a "pump and dump" scheme, intensified by ongoing political controversies surrounding Venezuela and the Epstein files.

Bank Of Nova Scotia

Bank of Nova Scotia is trending as recent dividend and share buyback announcements, coupled with a strategic investment in KeyCorp and multiple analyst upgrades, drive market conversation. Community discussion centers on whether the bank's pivot to North America and these positive developments will finally overcome its historical underperformance and perceived undervaluation among investors.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE CRYPTO is gaining traction as its passionate, 'cult-like' community highlights its unique narrative as the direct representation of Pepe by Matt Furie, demonstrating remarkable resilience and accumulation patterns on Ethereum amidst broader market downturns. The community remains fiercely dedicated, asserting it as a significantly undervalued micro-cap poised for substantial growth.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

ONDO is a major focus as positive news, including the closure of a multi-year SEC investigation and EU approval for tokenized stocks, reinforces its leadership in the Real World Asset (RWA) sector. Despite these bullish developments connecting traditional finance to blockchain, the community is actively debating the impact of a significant token unlock event on its future price action.

The Bank of Nova Scotia engages in the provision of financial products and services including personal, commercial, corporate, and investment banking. It operates through the following segments: Canadian Banking, International Banking, Global Wealth Management, Global Banking and Markets, and Other. The company was founded on March 30, 1832 and is headquartered in Toronto, Canada.

Bank of Nova Scotia is trending following a stronger-than-expected Q4 earnings report, which has fueled analyst upgrades and community discussions on its appealing dividend yield and potential for valuation expansion to align with its peers amidst a mixed market sentiment.

Newsmax Inc. is a holding company, which engages in television broadcasting and multi-platform content publishing that produces original news and editorial content for consumers through various media outlets, including TV new channels, digital and print publications. It operates through the Broadcasting and Digital Segments. The Broadcasting segment produces and licenses news, business news and lifestyle content for distribution through both MVPDs and free OTT streaming platforms. The Digital segment is composed of Newsmax.com and affiliated websites. The company was founded by Christopher Ruddy in 1998 and is headquartered in Boca Raton, FL.

Newsmax Inc. - Ordinary Shares - Class B

Newsmax Inc

Newsmax ($NMAX) is a contentious trending stock as its price hovers near all-time lows, fueling debate among investors who anticipate a rebound driven by recent multi-year distribution deals and Q3 earnings, while others highlight its significant decline from IPO highs and ongoing political associations with figures like Donald Trump.

Volatility Shares Trust - 2x Bitcoin Strategy ETF

Volatility Shares 2x Bitcoin Strategy ETF

BITX is trending as Bitcoin navigates significant price volatility, driving active community debate between those aggressively accumulating for a potential major rally and others cautioning against its 2x leveraged structure and observed volatility decay compared to Bitcoin's all-time highs. Discussions frequently highlight the ETF's monthly dividends and its performance relative to the broader crypto market.

Bunge Global SA engages in agribusiness including food and ingredients. It operates through the following segments: Agribusiness, Refined & Specialty Oils, Milling, Sugar & Bioenergy, and Corporate & Other. The Agribusiness segment is an integrated, global business principally involved in the purchase, storage, transportation, processing and sale of agricultural commodities and commodity products. The Refined & Specialty Oils segment includes businesses that sell vegetable oils and fats, including cooking oils, shortenings, specialty ingredients, and renewable diesel feedstocks. The Milling segment refers to the businesses that sell wheat flours, bakery mixes, and corn-based products. The Sugar & Bioenergy segment consists of results from the company’s previously owned 50% ownership interest in BP Bunge Bioenergia. The Corporate & Other segment focuses on the salaries and overhead for corporate functions that are not allocated to individual reporting segments because the operating performance of such reporting segments is evaluated. It connects farmers to consumers to deliver essential and sustainable food, feed and fuel. The company was founded on February 14, 2023 and is headquartered in Chesterfield, MO.

Bunge Global SA

Bunge Ltd.

Bunge is actively discussed for its recently completed Viterra merger, which is anticipated to yield significant synergies and has led to multiple analyst upgrades and raised price targets. Investors are also noting its inclusion in the S&P 500 and its strategic moves into renewable fuels, positioning it as an undervalued agribusiness leader.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Mereo BioPharma Group's (MREO) Buy Rating Reaffirmed at BTIG Research

BTIG Research reaffirmed a "buy" rating and issued a $1.00 price objective on shares of Mereo BioPharma Group in a research note on Friday...

Mereo BioPharma Group (NASDAQ:MREO) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered Mereo BioPharma Group from a "hold" rating to a "sell" rating in a report on Saturday...

Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO)

Mereo BioPharma Group plc - Sponsored ADR (NASDAQ:MREO - Get Free Report) was the target of some unusual options trading activity on Wednesday. Stock investors acquired 4,381 call options on the...

RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint

Ultragenyx and Mereo BioPharma shares fall as phase III Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta miss primary endpoints.

Nasdaq Falls Over 100 Points Amid Decline In Tech Stocks: Investor Sentiment Weakens, Fear & Greed Index In 'Neutral' Zone

U.S. stocks fell on Monday, with Nasdaq down 100 points. Nvidia Corp. and Mereo BioPharma Group plc also experienced declines.read more...

<ul class="summary-bullets"><li>The company said that results from the Phase 3 Orbit and Cosmic studies for an experimental drug designed to help people with brittle bone disease did not significantly reduce annualized clinical fracture rates.</li><li>Both studies showed improvements in bone mineral density, the company said.&nbsp;</li><li>Ultragenyx also noted that it will reduce expenses significantly after evaluating its planned operations.</li></ul>Ultragenyx Pharmaceutical Inc. (RARE) shares plunged over 41% on Monday after the company announced disappointing results from its Phase 3 studies for its experimental drug designed to help people with brittle bone disease.The company said that results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis Imperfecta (OI), conducted in partnership with Mereo Biopharma (MREO), did not significantly reduce annualized clinical fracture rates compared to placebo or bisphosphonates, respectively. However, both studies showed improvements in bone mineral density, the company said.The firm also said it will significantly reduce expenses after evaluating its planned operations.<h2 class="st-heading-2">Trial Details</h2>In the Orbit study, participants showed substantial improvements in bone mineral density compared with the placebo group. However, that did not result in a significant reduction in annualized fracture rates, since the placebo group also had a low fracture rate, the company noted.In the Cosmic study, which included pediatric patients, the baseline fracture rate was substantially higher than in the Orbit patient group. While the study showed improvements in bone mineral density and a reduction in annualized fracture rate compared to bisphosphonate-treated patients, the results were not statistically significant.“We are surprised and disappointed by these results given the promising data from our Phase 2 study and the lack of approved treatment options available to patients with OI who live with significant pain, disability, and disease burden,” said Emil Kakkis, chief executive officer and president of Ultragenyx. “We continue to explore the data to gain deeper understanding of the findings.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RARE">RARE shares</a> jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. The stock was also among the top trending tickets on the platform.<figure class="image"><img style="aspect-ratio:1283/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_29_at_9_02_19_PM_png_233d427277.webp" alt="On Stocktwits, retail sentiment around RARE shares jumped to ‘extremely bullish’ from ‘bearish’ territory over the past day, while message levels jumped to ‘extremely high’ levels at the time of writing. " width="1283" height="153"></figure>Shares of RARE are down over 51% in the past year.Editor's Note: The story has been updated to reflect that the Phase 3 Orbit and Cosmic studies for setrusumab in Osteogenesis Imperfecta was conducted in partnership with Mereo Biopharma.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

In this photo illustration, the Ultragenyx Pharmaceutical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Did RARE Stock Plunge Over 41% Today?

Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program. 

Equity

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

MREO
Mereo Biopharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MREO News

MREOMereo Biopharma